| Utpal Mondal, MD | |
|
5323 Harry Hines Boulevard, Dallas, TX 75390-7208 | |
| (214) 645-0624 | |
| (214) 645-0078 |
| Full Name | Utpal Mondal |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Location | 5323 Harry Hines Boulevard, Dallas, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578726923 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD151262 (Oregon) | Secondary |
| 208M00000X | Hospitalist | P8807 (Texas) | Primary |
| Entity Name | Christus Trinity Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285684225 PECOS PAC ID: 3072426741 Enrollment ID: O20031204001091 |
News Archive
A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.
Researchers at the Douglas Mental Health University Institute, have discovered a new genetic process that could one day provide a novel target for the treatment of neurodevelopmental disorders, such as intellectual disability and autism.
Although Obamacare's health insurance expansion has directly provided coverage to only about 4 percent of Americans, changes embedded in the Affordable Care Act could affect many more people, and not always in good ways.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
The Center for Health Value Innovation, the nation's premier information exchange for value-based design, today joined with other non-profits, healthcare provider groups, universities, government officials, and corporations to fully support the National Diabetes Goal (NDG) which aims to increase awareness and improve the management of type 2 Diabetes to the 45 percent of Americans at risk.
› Verified 1 days ago
| Entity Name | Southwest Medical Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831299122 PECOS PAC ID: 6204882947 Enrollment ID: O20050325000524 |
News Archive
A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.
Researchers at the Douglas Mental Health University Institute, have discovered a new genetic process that could one day provide a novel target for the treatment of neurodevelopmental disorders, such as intellectual disability and autism.
Although Obamacare's health insurance expansion has directly provided coverage to only about 4 percent of Americans, changes embedded in the Affordable Care Act could affect many more people, and not always in good ways.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
The Center for Health Value Innovation, the nation's premier information exchange for value-based design, today joined with other non-profits, healthcare provider groups, universities, government officials, and corporations to fully support the National Diabetes Goal (NDG) which aims to increase awareness and improve the management of type 2 Diabetes to the 45 percent of Americans at risk.
› Verified 1 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20100317001021 |
News Archive
A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.
Researchers at the Douglas Mental Health University Institute, have discovered a new genetic process that could one day provide a novel target for the treatment of neurodevelopmental disorders, such as intellectual disability and autism.
Although Obamacare's health insurance expansion has directly provided coverage to only about 4 percent of Americans, changes embedded in the Affordable Care Act could affect many more people, and not always in good ways.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
The Center for Health Value Innovation, the nation's premier information exchange for value-based design, today joined with other non-profits, healthcare provider groups, universities, government officials, and corporations to fully support the National Diabetes Goal (NDG) which aims to increase awareness and improve the management of type 2 Diabetes to the 45 percent of Americans at risk.
› Verified 1 days ago
| Entity Name | Inpatient Care Of South Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124464235 PECOS PAC ID: 0143461772 Enrollment ID: O20130724000773 |
News Archive
A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.
Researchers at the Douglas Mental Health University Institute, have discovered a new genetic process that could one day provide a novel target for the treatment of neurodevelopmental disorders, such as intellectual disability and autism.
Although Obamacare's health insurance expansion has directly provided coverage to only about 4 percent of Americans, changes embedded in the Affordable Care Act could affect many more people, and not always in good ways.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
The Center for Health Value Innovation, the nation's premier information exchange for value-based design, today joined with other non-profits, healthcare provider groups, universities, government officials, and corporations to fully support the National Diabetes Goal (NDG) which aims to increase awareness and improve the management of type 2 Diabetes to the 45 percent of Americans at risk.
› Verified 1 days ago
| Entity Name | Ipc Healthcare Services Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023403011 PECOS PAC ID: 3971824939 Enrollment ID: O20150603001409 |
News Archive
A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.
Researchers at the Douglas Mental Health University Institute, have discovered a new genetic process that could one day provide a novel target for the treatment of neurodevelopmental disorders, such as intellectual disability and autism.
Although Obamacare's health insurance expansion has directly provided coverage to only about 4 percent of Americans, changes embedded in the Affordable Care Act could affect many more people, and not always in good ways.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
The Center for Health Value Innovation, the nation's premier information exchange for value-based design, today joined with other non-profits, healthcare provider groups, universities, government officials, and corporations to fully support the National Diabetes Goal (NDG) which aims to increase awareness and improve the management of type 2 Diabetes to the 45 percent of Americans at risk.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Utpal Mondal, MD P.o. Box 845347, Dallas, TX 75284-5347 Ph: (214) 645-0624 | Utpal Mondal, MD 5323 Harry Hines Boulevard, Dallas, TX 75390-7208 Ph: (214) 645-0624 |
News Archive
A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.
Researchers at the Douglas Mental Health University Institute, have discovered a new genetic process that could one day provide a novel target for the treatment of neurodevelopmental disorders, such as intellectual disability and autism.
Although Obamacare's health insurance expansion has directly provided coverage to only about 4 percent of Americans, changes embedded in the Affordable Care Act could affect many more people, and not always in good ways.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
The Center for Health Value Innovation, the nation's premier information exchange for value-based design, today joined with other non-profits, healthcare provider groups, universities, government officials, and corporations to fully support the National Diabetes Goal (NDG) which aims to increase awareness and improve the management of type 2 Diabetes to the 45 percent of Americans at risk.
› Verified 1 days ago
Preetha Nair, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Boulevard, Dallas, TX 75390 Phone: 214-645-0624 Fax: 214-645-0078 | |
Michael Burton, MD, MSPH Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-3597 | |
Lavanya Ambujaa Dharmarajan, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 6201 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-633-5555 | |
Roshni Patel, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 8230 Walnut Hill Ln Ste 620, Dallas, TX 75231 Phone: 214-373-3475 | |
Dr. Apurva Yeluru, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3500 Gaston Ave Ste 550, Dallas, TX 75246 Phone: 214-820-0111 | |
Dr. Nicholas Ragovis, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 5200 Harry Hines Blvd, Dallas, TX 75235 Phone: 214-590-8000 Fax: 212-289-6393 | |
Kenneth Carter Raney, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1441 N Beckley Avenue, Dept Of Medical Education, Dallas, TX 75203 Phone: 214-947-2300 |